Table 1.
Summary of studies included in the present meta-analysis.
| Authors | Year | Study design | N | Gender (M/F) | Age | Region | Stage | Treatment | Line | Cut-off value | Outcomes | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lihong | 2019 | Retrospective | 102 | 87/15 | 62 | Asia | III-IV | Nivo, Pemb, Toripa, Sinti |
un-selected | 45 | OS,PFS | 7 |
| Taichi | 2020 | Retrospective | 24 | 7/17 | 64.5 (54.8–74.2) | Asia | III-IV | Atezo | >1 | 40 | OS | 5 |
| Cipriano | 2020 | Retrospective | 34 | 27/17 | 67 (34–79) | Europe | IV | Immunotherapy | un-selected | 50 | OS | 4 |
| Shi | 2021 | Retrospective | 103 | 68/35 | 66 | Asia | III-IV | Immunotherapy/Chemoimmunotherapy | un-selected | 45 | OS,PFS | 7 |
| Cinzia | 2021 | Retrospective | 44 | 26/18 | 70 (42–83) | Europe | III-IV | Pemb | 1 | 45.1 | PFS | 8 |
| Taisuke | 2021 | Retrospective | 36 | 31/5 | 68.5 | Asia | III-IV | Chemoimmunotherapy | 1 | 40 | OS,PFS | 6 |
| Junichi | 2021 | Retrospective | 73 | 52/21 | 70.9 (46–89) | Asia | III-IV | Nivo, Pemb,Atezo | un-selected | 43 | OS,PFS | 7 |
| Yuri | 2021 | Retrospective | 34 | 29/5 | 72 (55–81) | Asia | IV | Chemoimmunotherapy | 1 | 40 | OS,PFS | 6 |
| Na | 2021 | Retrospective | 123 | 98/25 | 59.9 (48.6–71.2) | Asia | IV | Nivo, Pemb, Sinti, Camre, Toripa |
un-selected | 46.05 | OS,PFS | 6 |
| Cipriano | 2021 | Retrospective | 52 | 42/10 | NR | Europe | IV | Immunotherapy | un-selected | 50 | OS,PFS | 4 |
| Stares | 2022 | Retrospective | 219 | 109/110 | 69 | Europe | III-IV | Pemb | 1 | 45 | OS,PFS | 8 |
| Satomi | 2022 | Retrospective | 237 | 187/187 | 69 (62–73) | Asia | IV | Chemoimmunotherapy | un-selected | 40.35 | OS,PFS | 7 |
| Naoki | 2022 | Retrospective | 38 | 30/8 | 75 (45–86) | Asia | III-IV | Pemb | 1 | 40 | PFS | 6 |
N, number; M, male; F, female; NR, not reported; OS, overall survival; PFS, progression-free survival; Nivo, Nivolumab; Pemb, Pembrolizumab; Toripa, Toripalimab; Sinti, Sintilimab; Camre, Camrelizumab; Atezo, Atezolizumab; NOS, Newcastle-Ottawa quality assessment Scale.